Anlon Healthcare P/E Ratio
Current P/E Ratio
29.24
High Valuation
High - Growth expectations or overvalued
Anlon Healthcare (AHCL) P/E ratio is 29.24 (High), EPS (TTM) ₹5.93, current price ₹15.95 on NSE — High - Growth expectations or overvalued. For live price, revenue and the complete fundamental profile, see AHCL screener.
Current Valuation Metrics
P/E Ratio
29.24
Current Price
₹15.95
EPS (TTM)
₹5.93
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
52.92
Sector Median
30.68
Sector Rank
#11 of 194
Sector Percentile
5.7%
Earnings Breakdown (TTM)
TTM EPS
₹8.61
Mar 2026
₹2.33
Mar 2025
₹5.15
AHCL P/E Ratio — Valuation Signal & Historical Context
Anlon Healthcare P/E 29.24 — signal: Overvalued. Browse AHCL cash flow statement for revenue, profit, balance sheet and cash flow data.
- Stock appears overvalued with PE of 29.24, suggesting caution for new investments
- Trading at discount to sector average PE of 52.92
AHCL vs Healthcare Peers — P/E Ratio Comparison
Anlon Healthcare P/E 29.24 vs Healthcare average 52.92, median 30.68 — range 2.86–850.0.
Sector Average
52.92
Sector Median
30.68
Lowest P/E
2.86
Highest P/E
850.0
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.64 | ₹29 | Low |
| Phaarmasia | PHRMASI | 4.06 | ₹68 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.97 | ₹7,724 | Low |
| Shelter Pharma | SHELTER | 5.45 | ₹48 | Low |
| Mono Pharmacare | MONOPHARMA | 6.51 | ₹20 | Low |
| Amwill Health Care | AMWILL | 7.33 | ₹78 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹71 | Low |
| Brooks Laboratories | BROOKS | 8.06 | ₹206 | Low |
| Royal Sense | ROYAL | 8.08 | ₹62 | Low |